Vanda Pharmaceuticals Inc. (VNDA)

Market Cap	262.97M
Revenue (ttm)	190.86M
Net Income (ttm)	-16.39M
Shares Out	58.31M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	486,389
Open	4.387
Previous Close	4.360
Day's Range	4.387 - 4.525
52-Week Range	3.460 - 6.750
Beta	0.77
Analysts	Strong Buy
Price Target	15.50 (+243.68%)
Earnings Date	Feb 5, 2025

About VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 12, 2006
• Employees: 203
• Stock Exchange: NASDAQ
• Ticker Symbol: VNDA
• Website: https://www.vandapharma.com

Financial Performance

In 2023, Vanda Pharmaceuticals's revenue was $192.64 million, a decrease of -24.27% compared to the previous year's $254.38 million. Earnings were $2.51 million, a decrease of -60.02%.

Analyst Forecast

According to 2 analysts, the average rating for VNDA stock is "Strong Buy." The 12-month stock price forecast is $15.5, which is an increase of 243.68% from the latest price.

Price Target

$15.5

(243.68% upside)

Analyst Consensus: Strong Buy